![]() ![]() ( AMGN), carrying a Zacks Rank #1 (Strong Buy). It has also filed regulatory application for the candidate in the EU. A better-ranked stock in the health care sector is Amgen Inc. Kite Pharma (KITE) shares hit a new 52-week high as the companys CAR-T therapy with axicabtagene ciloleucel nears an FDA nod. Kite Pharma carries a Zacks Rank #3 (Hold). KTE-C19, being the lead candidate in Kite Pharma’s pipeline, we expect investor focus to remain on updates on its development. Seattle Genetics ( SGEN) is currently developing SGN-CD19A for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. We note that Gilead’s ( GILD) Zydelig is approved by the FDA for the treatment of relapsed follicular B-cell non-Hodgkin lymphoma. Patient enrolment in this study is expected to begin in the first half of 2015. Kite Pharma intends to file an investigational new drug ( IND) application in the fourth quarter of 2014 for the commencement of a phase I-II single-arm multi-center study on KTE-C19 for the treatment of DLBCL patients who have failed two or more lines of therapy. Among these 4 patients, 3 are showing ongoing complete responses with durations ranging from 9 to 22 months. Additionally, 4 of the 7 chemotherapy-refractory DLBCL patients achieved complete remission, while 2 showed partial remission. In the phase I-II study, KTE-C19 achieved 92% overall objective response rate.Īccording to Kite Pharma, out of 13 patients with advanced B-cell malignancies (including 7 patients with chemotherapy-refractory diffuse large B cell lymphoma (:DLBCL)), 8 achieved complete remission, while 4 achieved partial remission. ( KITE) announced the publication of positive results from an ongoing phase I-IIa study on KTE-C19 in patients suffering from aggressive non-Hodgkin's lymphoma in the issue of the American Society of Clinical Oncology's Journal of Clinical Oncology. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |